Suppr超能文献

布洛芬联合抗真菌药物抗申克孢子丝菌活性的研究

Anti-Sporothrix activity of ibuprofen combined with antifungal.

机构信息

Laboratório de Biologia Celular de Fungos, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Avenida Carlos Chagas Filho 373, Centro de Ciências da Saúde, Bloco G, Sala G0-044, Rio de Janeiro, RJ, 21941-902, Brazil.

Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

出版信息

Braz J Microbiol. 2021 Mar;52(1):101-106. doi: 10.1007/s42770-020-00327-9. Epub 2020 Jul 2.

Abstract

The in vitro activity of ibuprofen, a nonsteroidal anti-inflammatory drug, was evaluated against Sporothrix brasiliensis and S. schenckii, either alone or in combination with amphotericin B, itraconazole, or terbinafine. The inhibitory activity of ibuprofen as a single agent was determined according to minimum inhibitory concentration (MIC) values, while the effect of ibuprofen combined with amphotericin B, itraconazole, or terbinafine was estimated by microdilution checkerboard methodology. The ultrastructural alterations of S. schenckii after exposure to the combination of ibuprofen and amphotericin B were evaluated by scanning electron microscopy (SEM) and flow cytometry analysis. As a single agent, ibuprofen inhibited Sporothrix growth with a MIC median of 256 μg/mL, while the MIC medians of ibuprofen in combination with antifungals were 16 μg/mL and 128 μg/mL. The MIC values of amphotericin B, itraconazole, and terbinafine were reduced when isolates were co-incubated with ibuprofen, mainly the polyene. The major alteration after treatment with the ibuprofen/amphotericin B combination was the increase in the presence of filamentous forms and high membrane damage with loss of plasma membrane integrity. In summary, we demonstrated that ibuprofen increases the in vitro activity of antifungals, mainly amphotericin B, against S. brasiliensis and S. schenckii. Future in vivo studies exploring combination therapy with ibuprofen and antifungals in animal models are needed to confirm its efficacy.

摘要

非甾体抗炎药布洛芬对巴西利什孢子丝菌和申克孢子丝菌的体外活性进行了评估,单独使用或与两性霉素 B、伊曲康唑或特比萘芬联合使用。根据最低抑菌浓度 (MIC) 值确定布洛芬作为单一药物的抑制活性,而通过微量稀释棋盘法评估布洛芬与两性霉素 B、伊曲康唑或特比萘芬联合使用的效果。通过扫描电子显微镜 (SEM) 和流式细胞术分析评估了布洛芬与两性霉素 B 联合使用后对申克孢子丝菌超微结构的改变。作为单一药物,布洛芬抑制孢子丝菌生长的 MIC50 中位数为 256μg/mL,而与抗真菌药物联合使用时的 MIC50 中位数分别为 16μg/mL 和 128μg/mL。当分离物与布洛芬共同孵育时,两性霉素 B、伊曲康唑和特比萘芬的 MIC 值降低,主要是多烯类。与布洛芬/两性霉素 B 联合治疗后,主要改变是丝状形式的增加和高膜损伤,导致质膜完整性丧失。总之,我们证明布洛芬可增加巴西利什孢子丝菌和申克孢子丝菌对抗真菌药物(主要是两性霉素 B)的体外活性。需要在动物模型中进行探索布洛芬与抗真菌药物联合治疗的未来体内研究,以确认其疗效。

相似文献

1
Anti-Sporothrix activity of ibuprofen combined with antifungal.布洛芬联合抗真菌药物抗申克孢子丝菌活性的研究
Braz J Microbiol. 2021 Mar;52(1):101-106. doi: 10.1007/s42770-020-00327-9. Epub 2020 Jul 2.

引用本文的文献

3
: Epidemiology, Therapy, and Recent Developments.流行病学、治疗方法及最新进展
J Fungi (Basel). 2023 Sep 13;9(9):921. doi: 10.3390/jof9090921.
4
Can nonsteroidal anti-inflammatory drugs (NSAIDs) be repurposed for fungal infection?非甾体抗炎药(NSAIDs)可被重新用于真菌感染吗?
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jan;397(1):59-75. doi: 10.1007/s00210-023-02651-x. Epub 2023 Aug 17.
6
Drug repurposing strategies in the development of potential antifungal agents.药物重定位策略在潜在抗真菌药物开发中的应用。
Appl Microbiol Biotechnol. 2021 Jul;105(13):5259-5279. doi: 10.1007/s00253-021-11407-7. Epub 2021 Jun 21.

本文引用的文献

1
The threat of emerging and re-emerging pathogenic Sporothrix species.新兴和重现的致病孢子丝菌物种的威胁。
Mycopathologia. 2020 Oct;185(5):813-842. doi: 10.1007/s11046-020-00425-0. Epub 2020 Feb 12.
6
Antifungal therapeutics for dimorphic fungal pathogens.用于双相真菌病原体的抗真菌治疗药物。
Virulence. 2017 Feb 17;8(2):211-221. doi: 10.1080/21505594.2016.1235653. Epub 2016 Sep 19.
9
Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs.阿司匹林和布洛芬作为抗隐球菌候选药物的重新利用
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4799-808. doi: 10.1128/AAC.02810-15. Print 2016 Aug.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验